Establishment of a histiocytic sarcoma cell line and anti-tumor effect of bortezomib in the African pygmy hedgehog (<i>Atelerix albiventris</i>)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Establishment of a histiocytic sarcoma cell line and anti-tumor effect of bortezomib in the African pygmy hedgehog (<i>Atelerix albiventris</i>)

Published:2024 Issue:8 Volume:86 Page:833-840
ISSN:0916-7250
Container-title:Journal of Veterinary Medical Science
language:en
Short-container-title:J. Vet. Med. Sci.

Author:

INANAGA Sakuya¹,SHIMODA Hiroshi²,IGASE Masaya¹,KONDO Hirotaka³,KOIZUMI Iori²⁴,MIZUNO Takuya¹

Affiliation:

1. Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan

2. Laboratory of Veterinary Microbiology, The United Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan

3. Laboratory of Veterinary Pathology, Department of Veterinary Medicine, Nihon University, Kanagawa, Japan

4. Koizumi Nest Animal Hospital, Fukuoka, Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Japanese Society of Veterinary Science

Link

https://www.jstage.jst.go.jp/article/jvms/86/8/86_23-0426/_pdf

Reference33 articles.

1. 1. Adams J. 2004. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349–360.

2. 2. Burgin CJ, Collella JP, Kahn PL, Upham NS. 2018. How many species of mammals are there?J Mammal 99: 1–14.

3. 3. Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E. National Cancer Institute of Canada Clinical Trials Group 2007. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1570–1575.

4. 4. Ciechanover A. 1994. The ubiquitin-proteasome proteolytic pathway. Cell 79: 13–21.

5. 5. Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. 2020. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 396: 186–197.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3